TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20484618
Drug: Oritavancin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 800 mg intravenously
Study: 20484618
Drug: Oritavancin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 200 mg intravenously
Study: 20484618
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg orally
Study: 16002807
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Zn supplementation
Study: 16002807
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Zn supplementation
Study: 16002807
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg Zn)
Study: 10214566
Drug: ADCON-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON-L
Study: 10214570
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ADCON-L)
Study: 2775143
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment based on the depression model
Study: 795498
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone combined with intravenous low‐molecular‐weight dextran (dextran 40)
Study: 22165359
Drug: Pharmacist medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist medication history only
Study: 15512838
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic (5g EMLA)
Study: 10930969
Drug: Tablet counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet counts
Study: 8857135
Drug: Hyoscine n‐butyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine n‐butyl bromide 20 mg
Study: 1996746
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg for induction followed by 6 mg/kg/hour for maintenance
Study: 1996746
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg/kg with enflurane 1% for maintenance
Study: 6374869
Drug: Basal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal and pentagastrin‐ and insulin‐stimulated acid outputs
Study: 30358536
Drug: AC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC regimen (doxorubicine 50 mg/m2, cyclophosphamide 500 mg/m2)
Study: 30358536
Drug: AC+Arglabin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC+Arglabin regimen (Arglabin 370 mg/m2 within 7 days)
Study: 30358536
Drug: Arglabin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arglabin as monotherapy
Study: 9535147
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg adrenocorticotropin 1‐24
Study: 31830404
Drug: Yoga exercises
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga exercises (three weekly sessions including meditation, breathing control, and slow body movements)
Study: 19645217
Drug: Diclofenac formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac formulations with sample size N = 12
Study: 19645217
Drug: Diclofenac formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac formulations with sample size N = 24
Study: 16210020
Drug: 1 micromol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 micromol/L FF-MAS
Study: 16210020
Drug: 10 micromol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micromol/L FF-MAS
Study: 1682177
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose acetyl salicylic acid (ASA) 75 mg/day for 10 days
Study: 1682177
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for 10 days
Study: 1682177
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to ASA after conventional therapy
Study: 1682177
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to conventional therapy after ASA
Study: 6291355
Drug: Pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel pamoate (Combantrin) at a dose of 20 mg/kg body weight for 1‐3 days
Study: 21817186
Drug: nevirapine plus
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine plus lopinavir/ritonavir (533/133 mg twice daily)
Study: 21817186
Drug: zidovudine/lamivudine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: zidovudine/lamivudine plus lopinavir/ritonavir (400/100 mg twice daily)
Study: 19927228
Drug: Existing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatment options for osteoporosis and fracture prevention, including potent antiresorptive and anabolic agents.
Study: 9777834
Drug: Desmopressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (1 microg bolus every 2 h when diuresis > 300 mL/h)
Study: 3182117
Drug: Fenticonazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole 2% lotion, applied once daily for three weeks
Study: 3182117
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% lotion, applied once daily for three weeks
Study: 29463461
Drug: Inhaled isopropyl
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isopropyl alcohol and 4 mg oral ondansetron
Study: 29463461
Drug: Inhaled isopropyl
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isopropyl alcohol and oral placebo
Study: 29463461
Drug: Inhaled saline
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled saline solution placebo and 4 mg oral ondansetron
Study: 20646533
Drug: GnRH‐a combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a combined with estradiol valerate 0.5 mg and dydrogesteronea 5 mg daily
Study: 11868798
Drug: AmB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB and oral spironolactone 100 mg twice daily
Study: 7781578
Drug: Sacroiliac joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacroiliac joint manipulation with EMLA cream
Study: 7418570
Drug: Radical Co60
Normalized name: CAMPSIS RADICANS FLOWER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical Co60 therapy + Methotrexate + 5-Fluorouracil
Study: 7418570
Drug: Co60 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co60 therapy alone
Study: 31750786
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (3 times a week for 6 weeks)
Study: 31182139
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (lisinopril) added to standard of care
Study: 27276835
Drug: Medical Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutritional Therapy (MNT) with Self Blood Glucose Monitoring (SBGM)
Study: 23551127
Drug: Routine early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine early tirofiban treatment
Study: 23551127
Drug: Deferred provisional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred provisional tirofiban treatment
Study: 19130293
Drug: SSKI (Saturated
Normalized name: SSKI (saturated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSKI (Saturated Solution Potassium Iodide)
Study: 17117398
Drug: NeuroPsychological Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroPsychological Training (TNP) plus cholinesterase inhibitors
Study: 17117398
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors alone
Study: 14757591
Drug: Combined psychotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psychotherapy (8 sessions of cognitive behavior therapy) plus pharmacotherapy (citalopram)
Study: 11158406
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (rHuEpo) therapy for 3 months
Study: 11158406
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (rHuEpo) therapy for 1 year
Study: 7519005
Drug: Selegiline 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 60 mg/d
Study: 28387017
Drug: Massage Therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage Therapy in Multisensory Environment (MT in MSE)
Study: 28387017
Drug: Massage Therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage Therapy (MT) alone
Study: 20852958
Drug: Alprazolam (anxiolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (anxiolytic medication)
Study: 20852958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication administered for anxiety reduction)
Study: 18635724
Drug: 17 mg
Normalized name: vitamin B6 17 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 mg THC
Study: 18635724
Drug: 13 mg
Normalized name: hemin 313 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg THC
Study: 18635724
Drug: 13 mg
Normalized name: hemin 313 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg and 17 mg THC
Study: 17065274
Drug: Single 2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-hour infusion of cetuximab at doses of 50, 100, 250, 400, or 500 mg/m2 followed by weekly 1-hour infusions of cetuximab at a fixed dose of 250 mg/m2
Study: 20625263
Drug: Zidovudine plus
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine plus standard-dose lopinavir/ritonavir (LPV/r) 300 mg zidovudine and 400/100 mg LPV/r twice daily from 28 weeks' gestation until delivery
Study: 15731312
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Crinone 8%) administered once a day for 5 days
Study: 15731312
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel without vaginal progesterone) administered once a day for 5 days
Study: 11568372
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg/kg bolus followed by 0.06 mg/kg/h continuous infusion)
Study: 11568372
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 mg/kg bolus followed by 0.06 mg/kg/h continuous infusion)
Study: 11568372
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and morphine infusion (10 microg/kg/h)
Study: 11568372
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and morphine infusion (10 microg/kg/h)
Study: 9643277
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment initiated intravenously within 24 hours after acute myocardial infarction
Study: 7888290
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000 micrograms twice daily for 3.5 days
Study: 17171886
Drug: HD-HES (hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-HES (hydroxyethyl starch solution, ratio 1:1, n = 15)
Study: 27840299
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation (ES) administered over the lumbar paraspinal muscles for 60 minutes per day, three times per week, for 4 consecutive weeks
Study: 22428490
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 50 microg/min
Study: 22428490
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 100 microg/min
Study: 3068050
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of epinephrine plus polidocanol (group A)
Study: 3068050
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (group B)
Study: 18285316
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg + saquinavir 1000 mg twice daily (arm A)
Study: 18285316
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg + saquinavir 600 mg twice daily (arm B)
Study: 18285316
Drug: lopinavir/ritonavir 266/66
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 266/66 mg + saquinavir 1000 mg twice daily (arm C)
Study: 18285316
Drug: lopinavir/ritonavir 266/66
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 266/66 mg + saquinavir 600 mg twice daily (arm D)
Study: 10215657
Drug: W/O/W of
Approvals — FDA: no, EMA: no, PMDA: no
Description: W/O/W of small IPSO microdroplets (30 micrometers in diameter) containing 60 mg of epirubicin (group A)
Study: 10215657
Drug: W/O/W of
Approvals — FDA: no, EMA: no, PMDA: no
Description: W/O/W of large IPSO microdroplets (70 micrometers) containing 60 mg of epirubicin (group B)
Study: 7705673
Drug: rhu IL‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu IL‐3 administered after chemotherapy (250 and 500 micrograms)
Study: 7705673
Drug: rhu IL‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu IL‐3 administered before chemotherapy (50 micrograms)
Study: 2568661
Drug: CM6912 (ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM6912 (ethyl loflazepate) 1 mg twice daily (CM-1 group)
Study: 2568661
Drug: CM6912 (ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM6912 (ethyl loflazepate) 2 mg once daily (CM-2 group)
Study: 2568661
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZP) 2 mg three times daily
Study: 27330023
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg twice daily for four days then 4 mg twice daily for three days
Study: 21078804
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (group C)
Study: 12562577
Drug: Olanzapine, 7.5
Normalized name: Olanzapine, 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine, 7.5 mg/day
Study: 12562577
Drug: Haloperidol, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, 2.5 mg/day
Study: 8466259
Drug: Intravenous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous glucagon (200 micrograms/kg)
Study: 8466259
Drug: Intragastric medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric medium chain triglyceride (MCT) (5 ml/kg)
Study: 29378708
Drug: Plazomicin 10
Normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plazomicin 10 mg/kg
Study: 27310327
Drug: ASP2409 (0.001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2409 (0.001 to 3.0 mg/kg)
Study: 27310327
Drug: ASP2409 (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2409 (0.01 to 3.0 mg/kg)
Study: 21715138
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume mechanical ventilation (V(T), 6 mL/kg)
Study: 21715138
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume mechanical ventilation (V(T), 10 mL/kg)
Study: 18495607
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg 10 min before operation
Study: 18495607
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg 5 min before operation
Study: 18495607
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg 1 min before operation
Study: 18495607
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg (control group)
Study: 11240980
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with 20 mg of omeprazole or 30 mg of lansoprazole twice a day, 200 mg of clarithromycin three times a day, and 500 mg of amoxicillin three times a day for 1 week
Study: 11240980
Drug: Dual high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual high-dose lansoprazole (30 mg four times daily) and amoxicillin (500 mg four times daily) for 2 weeks
Study: 11240980
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with triple therapy
Study: 9772054
Drug: RCM (Rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCM (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Metronidazole 400 mg b.d.)
Study: 9772054
Drug: RAC (Rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Clarithromycin 500 mg b.d.)
Study: 9772054
Drug: RAM (Rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAM (Rabeprazole 20 mg b.d., Amoxycillin 1 g b.d., Metronidazole 400 mg b.d.)
Study: 9772054
Drug: RC (Rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC (Rabeprazole 20 mg b.d., Clarithromycin 500 mg b.d.)
Study: 1361746
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg), subcutaneously, three times a week for 24 weeks
Study: 1361746
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg), subcutaneously, three times a week for 52 weeks
Study: 19827277
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual conservative treatment: NSAIDs, local splinting, local heat)
Study: 17094417
Drug: FP (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP (5-FU 800 mg/m2/d in continuous infusion for 5 days and cisplatin 100 mg/m2 on day 1 or 2)
Study: 17094417
Drug: FLP (LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLP (LV 100 mg/m2/d in bolus for 5 days, followed by 5-FU 350 mg/m2/d in 1 h infusion for 5 days and cisplatin 100 mg/m2 on day 1 or 2)
Study: 28803880
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU bolus followed by 4000 IU daily)
Study: 25055933
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (50 μg every 4 h, maximum of 3 doses)
Study: 25055933
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone (0.5 mg every 2 h, maximum of 2 doses)
Study: 25055933
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol and intracervical dinoprostone
Study: 22151932
Drug: Lignin peroxidase
Normalized name: peroxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignin peroxidase cream (LIP)
Study: 19187507
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Study: 15289368
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 IU daily
Study: 16206671
Drug: Hydrotalcite 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotalcite 1.0 g four times daily for 6 weeks
Study: 16206671
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for the first 2 weeks and 20 mg once daily for the following 4 weeks
Study: 9738364
Drug: Ibuprofen L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen L-arginine 400 mg
Study: 9738364
Drug: Naproxen 550
Normalized name: naproxen sodium 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 550 mg
Study: 2468894
Drug: Potassium (KCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium (KCl, 20 mEq three times daily)
Study: 2468894
Drug: Calcium (Ca,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (Ca, 500 mg twice daily)
Study: 30239887
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (HDC) - mean initial dose 100 mg/m2
Study: 30239887
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (LDC) - mean initial dose 40 mg/m2
Study: 21665059
Drug: Support-person intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support-person intervention (written materials plus three weekly telephone sessions lasting 10-30 minutes each)
Study: 15320990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rev, tat, and nef intramuscularly at weeks 0, 4, and 16 at increasing doses (300, 900, and 1800 micrograms DNA)
Study: 15320990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rev, tat, and nef intramuscularly
Study: 15320990
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rev, tat, and nef in increasing doses
Study: 9330391
Drug: Japanese herbal
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese herbal medicine (Juzentaihotou or Hotyuekkitou)